Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR2 | O15552 | 1/20 | 0.36 |
| ▸ | CTSK | P43235 | 1/20 | 0.31 |
| ▸ | PTGES | O14684 | 2/20 | 0.31 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.31 |
| ▸ | MEF2D | Q14814 | 1/20 | 0.31 |
| ▸ | LGMN | Q99538 | 1/20 | 0.30 |
| ▸ | CDK8 | P49336 | 1/20 | 0.30 |
| ▸ | CDK19 | Q9BWU1 | 1/20 | 0.30 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3710734 | 0.87 | ATAD2 (0.35) | FFAR2 | |
| SCHEMBL3699081 | 0.78 | HTR2B (0.37) | — | |
| SCHEMBL3710524 | 0.77 | GABRA5 (0.31) | — | |
| SCHEMBL3698383 | 0.73 | MEN1 (0.45) | — | |
| SCHEMBL1990265 | 0.70 | LMNA (0.37) | FFAR2 | |
| SCHEMBL2142650 | 0.69 | MEN1 (0.59) | — | |
| SCHEMBL2711942 | 0.68 | MEN1 (0.38) | FFAR2HDAC4MEF2D | |
| SCHEMBL23528164 | 0.65 | FFAR2 (0.38) | FFAR2CTSK | |
| SCHEMBL577680 | 0.65 | CYP3A4 (0.39) | FFAR2CTSKHDAC4MEF2DCDK8 | |
| SCHEMBL9927079 | 0.65 | CTSK (0.44) | FFAR2CTSKPTGES |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090170783-A1 | NOVEL TETRAHYDROCARBAZOLE DERIVATIVES AS LIGANDS OF G-PROTEIN COUPLED RECEPTORS | AETERNA ZENTARIS GMBH (DE) | 2009-07-02 | — | — | US | claimed |
| US-8541462-B2 | Tetrahydrocarbazole derivatives as ligands of G-protein coupled receptors | AETERNA ZENTARIS GMBH (DE) | 2013-09-24 | — | — | US | disclosed |
| US-20120122763-A1 | NOVEL TETRAHYDROCARBAZOLE DERIVATIVES AS LIGANDS OF G-PROTEIN COUPLED RECEPTORS | AETERNA ZENTARIS GMBH (DE) | 2012-05-17 | — | — | US | disclosed |
| US-20090170783-A1 | NOVEL TETRAHYDROCARBAZOLE DERIVATIVES AS LIGANDS OF G-PROTEIN COUPLED RECEPTORS | AETERNA ZENTARIS GMBH (DE) | 2009-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170783-A1 | NOVEL TETRAHYDROCARBAZOLE DERIVATIVES AS LIGANDS OF G-PROTEIN COUPLED RECEPTORS | GPR88, GPR34, GPR27 | FFAR2 57/4885CTSK 2696/4885PTGES 1314/4885 |
| US-20120122763-A1 | NOVEL TETRAHYDROCARBAZOLE DERIVATIVES AS LIGANDS OF G-PROTEIN COUPLED RECEPTORS | GPR88, GPR34, GPR27 | FFAR2 57/4885CTSK 2696/4885PTGES 1314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.